India Pharma Outlook Team | Wednesday, 30 September 2026
Biodeal’s 135 million-unit buy shows India's CDMO capacity scramble and propels the company into a higher competitive tier.
Biodeal Pharmaceuticals acquires Biological E’s large sterile injectable facility in Paonta Sahib, Himachal Pradesh, and instantly adds scale that most contract manufacturers take years to build.
The site already delivers 135 million units a year and can expand by another 30 million.
This single deal moves Biodeal from two WHO-GMP plants into a regulated-market-ready platform and positions the firm to chase high-volume contracts in demanding global markets.
India’s broader race for sterile injectable capacity gains fresh momentum as global buyers diversify supply chains and seek reliable partners outside China.
Biodeal currently operates two WHO-GMP certified facilities focused on nasal delivery systems, specialty formulations and complex generics. The Paonta Sahib acquisition transforms that profile.
Spread across 14 acres with 39,000 square meters of built-up space, the plant ranks among the largest manufacturing sites in Himachal Pradesh. It runs 17 production lines equipped with German-made Groninger processing equipment and specializes in general injectables and Carbapenems in vial formats.
"This acquisition is a deliberate step, not an opportunistic one. RMB Capitalworks backed our growth path with conviction, and Paonta Sahib gives us a regulated-market manufacturing base with credentials and capabilities that normally take years to build. It changes the category of company Biodeal competes in and puts us in a strong position to continue building a durable, high-value regulated-market business," said Anurag Kumar, Chairman & Managing Director, Biodeal Pharmaceuticals.
The facility supplies an established sterile injectable platform, specialized capabilities and regulatory credentials that normally require years to develop.
Also Read: Sterile Injectable CDMO in India: Manufacturing, Fill-Finish, Technology & Regulatory Guide 2026
Biodeal plans to add pre-filled syringe and lyophilized product lines at the site. These formats deliver higher margins and enjoy strong preference among customers in regulated markets because they offer ready-to-use convenience and extended shelf life.
The company will pursue PIC/S and EU accreditation to unlock additional regulated markets. The total outlay for the acquisition and planned investments exceeds Rs 400 crore. Funding support arrives from RMB Capitalworks, which recently backed Biodeal with Rs 385 crore specifically to accelerate regulated-market growth.
Key capabilities the deal unlocks:
The transaction forms part of a wider scramble among Indian CDMOs to secure sterile injectable capacity. Global demand for these complex products continues to rise while buyers actively diversify supply chains away from single-country dependence.
India’s push to capture more regulated-market CDMO business gains concrete expression in deals such as this one. Biological E divests the Paonta Sahib site so it can concentrate investment on its new vaccine R&D and CDMO campus in Telangana.
"As Biological E continues to focus our investment on our new vaccine R&D and CDMO campus in Telangana, divesting our Paonta Sahib facility to a capable, growth-oriented partner was a natural next step. We are confident Biodeal Pharmaceuticals is well positioned to build on the strong foundation established at this facility, and we wish them continued success as they take it forward," said Mahima Datla, Managing Director, Biological E Limited.
Biodeal now holds both the scale and the specialized sterile manufacturing base required to compete for high-volume, high-value contracts. The 135 million unit platform, combined with plans for pre-filled syringes, lyophilized formats, and international accreditation, places the company firmly inside the capacity scramble that is reshaping India’s CDMO landscape.
.jpg)
